Abstract:Adenosine deaminase acting on RNA 1 (ADAR1) is an RNA-editing enzyme that catalyzes adenosine-to-inosine conversions in double-stranded RNAs (dsRNAs). In mammals, ADAR1 is composed of two isoforms: a nuclear short p110 isoform and a cytoplasmic long p150 isoform. Whereas both isoforms contain right-handed dsRNA-binding and deaminase domains, ADAR1 p150 harbors a Zα domain that binds to left-handed dsRNAs, termed Z-RNAs. Myeloma differentiation-associated gene 5 (MDA5) sensing of endogenous dsRNAs as non-self leads to the induction of type I interferon (IFN)-stimulated genes, but recent studies revealed that ADAR1 p150-mediated RNA editing, but not ADAR1 p110, prevents this MDA5-mediated sensing. ADAR1 p150-specific RNA-editing sites are present and at least a Zα domain-Z-RNA interaction is required for this specificity. Mutations in the ADAR1 gene cause Aicardi-Goutières syndrome (AGS), an infant encephalopathy with type I IFN overproduction. Insertion of a point mutation in the Zα domain of the Adar1 gene induces AGS-like encephalopathy in mice, which is rescued by concurrent deletion of MDA5. This finding indicates that impaired ADAR1 p150-mediated RNA-editing is a mechanism underlying AGS caused by an ADAR1 mutation. ADAR1 p150 also prevents ZBP1 sensing of endogenous Z-RNA, which leads to programmed cell death, via the Zα domain and its RNA-editing activity. Furthermore, ADAR1 prevents protein kinase R (PKR) sensing of endogenous right-handed dsRNAs, which leads to translational shutdown and growth arrest. Thus, ADAR1 acts as a regulatory hub that blocks sensing of endogenous dsRNAs as non-self by multiple sensor proteins, both in RNA editing-dependent and -independent manners, and is a potential therapeutic target for diseases, especially cancer.

N6-methyladenosine promotes induction of ADAR1-mediated A-to-I RNA editing to suppress aberrant antiviral innate immune responses

N6-Methyladenosines Modulate A-to-I RNA Editing.

RNA Editing, ADAR1, and the Innate Immune Response

ADAR-mediated RNA Editing in Non-Coding RNA Sequences

Multifaceted roles of RNA editing enzyme ADAR1 in innate immunity

The role of RNA editing enzyme ADAR1 in human disease

RNA editing by ADAR1 regulates innate and antiviral immune functions in primary macrophages

Adenosine Deaminases Acting on RNA, RNA Editing, and Interferon Action

Biological roles of A-to-I editing: implications in innate immunity, cell death, and cancer immunotherapy.

The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways

m6A modification controls the innate immune response to infection by targeting type I interferons

Deciphering the Biological Significance of ADAR1–Z-RNA Interactions

RNA editing regulates host immune response and T cell homeostasis in SARS-CoV-2 infection

Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA–triggered innate immune responses

N 6-Methyladenosine RNA Modification Suppresses Antiviral Innate Sensing Pathways Via Reshaping Double-Stranded RNA

Adenosine Deaminase Acting on RNA 1 Limits RIG-I RNA Detection and Suppresses IFN Production Responding to Viral and Endogenous RNAs.

N6-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA

Adenosine-to-inosine RNA editing in the immune system: friend or foe?

N &Lt;sup>6</sup>-Methyladenosine Modification on NS Segment Regulates Influenza a Virus Splicing and Replication

N6-methyladenosine modification of HIV-1 RNA suppresses type-I interferon induction in differentiated monocytic cells and primary macrophages

RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself